


SYNTHETIC STUDY OF 1-SUBSTITUTED CARBAPENEM ANTIBIOTICS

Tomoyuki Shibata, Kimio Iino, Teruo Tanaka, Toshihiko Hashimoto,
 Yukiko Kameyama and Yukio Sugimura*

Chemical Research Laboratories, Sankyo Co., Ltd.,
 Hiromachi, Shinagawa-ku, Tokyo, 140, Japan

Summary: Total synthesis of 1-substituted carbapenems is described. The key step is the reaction of acetoxyazetidinone (7) with ketene silyl acetal (8).

Since the discovery of thienamycin (1),¹⁾ because of its high antibacterial activity and broad spectrum, carbapenem antibiotics have attracted much attention. But 1 is chemically unstable and readily metabolized by renal dehydropeptidase-I (DHP-I). In the previous paper,²⁾ we reported the synthesis of RS-533 (2) which is more potent in activity and more stable than 1. On the other hand, D.H. Shih *et al.* synthesized 1- β -methyl-carbapenem 3 and found that introduction of a methyl substituent to the 1-positions of carbapenems was very effective in improving its metabolical stability.³⁾ We have also been interested in biological effect of some substituents introduced to the 1-position of RS-533. For the effective synthesis of 1- β -methylcarbapenems, stereoselective synthesis of β -Me isomer 6a ($R^1=CH_3$, $R^2=H$) is necessary as the key intermediate, but the Merck group's



method (treatment of 4 with 2 equiv. of LDA and MeI) gave α -Me isomer (5a) as the major product (5a:6a=4:1).³⁾ We now report an improved method for the preparation of β -Me isomer 6 and the synthesis of 1- β - and 1- α -methyl RS-533 (17 β and 17 α) as well as other 1-substituted carbapenems.

The key step of our synthesis is the reaction of acetoxyazetidinone 7 with ketene silyl acetal 8 in the presence of trimethylsilyl trifluoromethanesulfonate (TfO-TMS).⁴⁾ The results are summarized in Table I.




Table I


The reactions of <u>7</u> with <u>8</u>				
entry	<u>8</u> R^1, R^2	R^3	product	yield
a	Me, H	OMe	<u>5</u> and <u>6</u>	94% (<u>6</u> / <u>5</u> =1/2.6)
b	Me, H	SPh	<u>5</u> and <u>6</u>	81% (<u>6</u> / <u>5</u> =1.6/1)
c	OMe, H	STol(<i>m</i>)	<u>9</u>	68%
d	Me, Me	OEt	<u>10</u>	96%
e	Me, Me	STol(<i>p</i>)	<u>10</u>	46%

Ketene silyl acetal 8a ($R^1, R^2=Me, H; R^3=OMe$) reacted with 7 in CH_2Cl_2 at room temperature in the presence of a catalytic amount of TfO-TMS to afford a mixture of α -Me isomer (5a ($R^3=OMe$), major) and β -Me isomer (6a ($R^3=OMe$), minor). On the other hand, ketene silyl acetal 8b ($R^1, R^2=Me, H; R^3=SPh$; E:Z=6:1) afforded β -Me isomer (6b ($R^3=SPh$)) as the major product along with α -Me isomer (5b ($R^3=SPh$)), these isomers being easily separated by silica gel chromatography or recrystallization. And 8b (E:Z=1:6) afforded a same result.

Compound 5b and 6b were separated by silica gel chromatography and were hydrolyzed (aq. NaOH in MeOH) quantitatively to give 11 α and 11 β , respectively. According to the Merck method,³⁾ 11 α and 11 β were converted to 1- α -methyl-2-ketocarbapenam (12 α) and 1- β -isomer (12 β), respectively. 1- β -Methyl-2-ketocarbapenam (12 β) was readily converted to 14 β by the condensation reaction with 3-(S)-mercaptopyrrolidine derivative (13) almost quantitatively, and gave 1- β -methyl RS-533 (17 β)⁶⁾ after deprotection (PNB and PNZ) by catalytic hydrogenation (Pd-C in H_2O -THF) and successive treatment with ethoxyacetimidate in 57% yield.

On the other hand, the α -Me isomer (14 α) obtained from 12 α and 13 was very unstable and could not be isolated. So 12 α was converted to 16 α by the condensation reaction with (S)-mercaptoamidine derivative (15) (Y.43%). 16 α was more stable than 14 α , and gave 1- α -methyl RS-533 (17 α)⁶⁾ after deprotection by catalytic hydrogenation (Y.51%).

Analogously, 1-methoxy- (20) and 1,1-dimethyl-2-ketocarbapenams (21) were synthesized from 9 (R^3 =STol(*m*)) and 10 (R^3 =STol(*p*)), respectively. 20 was readily converted to 22 (Y.quant.), which gave 1-methoxy RS-533 (24)⁶⁾ by catalytic hydrogenation (Y.21%). These 1-methoxy compounds (9, 18, 20, 22 and 24) could not be separated to give α - and β -isomers. On the other hand, 21 could not be converted to 23 or 25 owing to steric hindrance of the 1,1-dimethyl group. We, therefore, applied Oida's method⁵⁾ to 10, and synthesized 27. 27 was cyclized *via* the intramolecular Wittig reaction to give 28 in 35% yield. 28 was treated with KF in aq.CH₃CN to afford 25 and successive treatment with ethoxyacetimidate gave 1,1-dimethyl RS-533 (26)⁶⁾ in 18% yield.



1- β -Methyl RS-533 (17 β) is highly resistant to enzymatic hydrolysis by DHP-I, and shows strong antibacterial activity and good bioavailability. 1- α -Methyl RS-533 (17 α), 1-methoxy RS-533 (24) and 1,1-dimethyl RS-533 (26) are also rather resistant to DHP-I but showed relatively weak antibacterial activities. The detailed antibacterial activities of these 1-substituted RS-533 will be reported elsewhere.

References.

1. (a) H. Kropp, J. S. Kahan, F. M. Kahan, J. Sandelof, G. Darland and J. Birnbaum, Abstract 228, 16th InterSci. Conf. Antimicrob. Agents and Chemother., Chicago, III. 1976; (b) J. S. Kahan, F. M. Kahan, R. Goegelman, S. A. Currie, M. Jackson, E. O. Stapley, T. W. Miller, A. K. Miller, D. Hendlin, S. Mochales, S. Hernandez, H. B. Woodruff and J. Birnbaum, J. Antibiot., 32, 1 (1980); (c) G. Albers-Schönberg, B. H. Arison, O. D. Hensens, J. Hirshfield, E. A. Kaczka, R. E. Rhodes, J. S. Kahan, F. M. Kahan, R. W. Ratcliffe, E. W. Walton, L. J. Ruswinkle, R. B. Morin and B. G. Christensen, J. Am. Chem. Soc., 100, 6491 (1978).
2. T. Miyadera, Y. Sugimura, T. Hashimoto, T. Tanaka, K. Iino, T. Shibata and S. Sugawara, J. Antibiot., 36, 1034 (1983).
3. (a) D. H. Shih, F. Baker, L. Cama and B. G. Christensen, Heterocycles, 21, 1 (1984); (b) D. H. Shih, J. A. Fayter, L. D. Cama, B. G. Christensen and J. Hirshfield, Tetrahedron Lett., 26, 583 (1985); (c) D. H. Shih, L. Cama and B. G. Christensen, Tetrahedron Lett., 26, 587 (1985).
4. A. G. Barrett and P. Quayle, J. C. S., Chem. Comm., 1981, 1076.
5. A. Yoshida, Y. Tajima, N. Takeda and S. Oida, Tetrahedron Lett., 25, 2793 (1984).
6. Spectra Data: 17 α : UV λ_{\max} 290nm (ϵ 4800); IR (KBr) 3400, 1765, 1685, 1635, 1600 cm^{-1} ; NMR (400MHz, in D_2O , ppm) 1.09(3H, d, $J=7\text{Hz}$), 1.16(3H, d, $J=7$), 1.8-2.0(1H, m), 2.07, 2.08 (each 1.5H, s), 2.1-2.3(1H, m), 3.05-3.2(1H, m), 3.2-3.95(7H, m), 4.0-4.1(1H, m). 17 β : UV λ_{\max} 297nm (ϵ 8700); IR (KBr) 3400, 1755, 1680, 1635, 1590 cm^{-1} ; NMR (400MHz, in D_2O , ppm) 1.04(3H, d, $J=7$), 1.10(3H, d, $J=6$), 1.85-2.05(1H, m), 2.05, 2.09 (each 1.5H, s), 2.25-2.4(1H, m), 3.15-3.95(7H, m), 4.0-4.15(2H, m). 24: UV λ_{\max} 297nm (ϵ 5500); IR (KBr) 3330, 1765, 1675, 1590 cm^{-1} ; NMR (400MHz, in D_2O , ppm) 1.13-1.18(3H, m), 1.87-2.02(1H, m), 2.22-2.36(1H, m), 2.05, 2.07, 2.09, 2.10(3H, each s), 3.29, 3.31(3H, each s), 3.4-4.15(9H, m). 26: UV λ_{\max} 280nm (ϵ 5300); IR (KBr) 3350, 1755, 1670, 1630, 1600 cm^{-1} ; NMR (90MHz, in D_2O , ppm) 0.92(3H, s), 1.09(3H, d, $J=6\text{Hz}$), 1.13(3H, s), 2.06(3H, s), 1.56-2.58(2H, m), 3.06-4.25(8H, m).

(Received in Japan 9 July 1985)